Literature DB >> 32647632

How to Best Detect Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Meeting the Milan Criteria: Gadoxetic Acid-Enhanced MRI versus Contrast-Enhanced CT.

Jae Seok Bae1,2, Jeong Min Lee1,2,3, Jeong Hee Yoon1,2, Siwon Jang4, Jin Wook Chung1,2,3, Kyung Bun Lee5, Nam-Joon Yi6, Jeong-Hoon Lee7.   

Abstract

INTRODUCTION: The detection of portal vein tumor thrombosis (PVTT) in patients with hepatocellular carcinoma (HCC) meeting the Milan criteria is of critical importance as PVTT is known to be a contraindication to transplantation and an indicator of a dismal prognosis.
OBJECTIVE: To determine which modality may best detect PVTT, we compared the diagnostic performance of gadoxetic acid-enhanced MRI (GA-MRI) and contrast-enhanced CT (CECT) in HCC patients meeting the Milan criteria.
METHODS: We retrospectively enrolled 310 patients with HCCs meeting the Milan criteria who underwent both GA-MRI and CECT between June 2007 and May 2017. Among them, 44 patients were demonstrated to have PVTT while 266 patients had no PVTT. Two radiologists then assessed GA-MRI and CECT images for the presence of PVTT on a 5-point scale as well as vessel expansion, continuity with tumors, and enhancement on both modalities, as well as T2 hyperintensity and diffusion restriction on GA-MRI. The McNemar test was used to compare sensitivity and specificity of GA-MRI and CECT for the detection of PVTT, and Fisher's exact test was used to compare their imaging features.
RESULTS: GA-MRI showed higher sensitivity values than CECT in detecting PVTT (reviewer 1, 93.2% [41/44] vs. 77.3% [34/44]; reviewer 2, 88.6% [39/44] vs. 70.5% [31/44]) (both p = 0.039). Specificity of GA-MRI and CECT demonstrated no difference (reviewer 1, 95.5% [254/266] vs. 95.1% [253/266]; reviewer 2, 97.0% [258/266] vs. 97.4% [259/266]) (both p > 0.999). Continuity with tumors and enhancement were more frequently observed on GA-MRI than on CECT (p < 0.050, both reviewers).
CONCLUSION: GA-MRI detected PVTT more often than CECT in HCC patients meeting the Milan criteria and better depicted PVTT in continuity with tumors and those showing enhancement than CECT.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Contrast-enhanced CT; Gadoxetic acid-enhanced MRI; Hepatocellular carcinoma; Portal vein thrombosis

Year:  2020        PMID: 32647632      PMCID: PMC7325130          DOI: 10.1159/000505191

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  46 in total

1.  Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome.

Authors:  M A Yerdel; B Gunson; D Mirza; K Karayalçin; S Olliff; J Buckels; D Mayer; P McMaster; J Pirenne
Journal:  Transplantation       Date:  2000-05-15       Impact factor: 4.939

2.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  Eur J Cancer       Date:  2012-03       Impact factor: 9.162

3.  Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.

Authors:  T J Vogl; S Kümmel; R Hammerstingl; M Schellenbeck; G Schumacher; T Balzer; W Schwarz; P K Müller; W O Bechstein; M G Mack; O Söllner; R Felix
Journal:  Radiology       Date:  1996-07       Impact factor: 11.105

4.  Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation.

Authors:  Fabio Piscaglia; Alice Gianstefani; Matteo Ravaioli; Rita Golfieri; Alberta Cappelli; Emanuela Giampalma; Elisabetta Sagrini; Grazia Imbriaco; Antonio Daniele Pinna; Luigi Bolondi
Journal:  Liver Transpl       Date:  2010-05       Impact factor: 5.799

5.  Characterization of Portal Vein Thrombosis (Neoplastic Versus Bland) on CT Images Using Software-Based Texture Analysis and Thrombus Density (Hounsfield Units).

Authors:  Rodrigo Canellas; Farhad Mehrkhani; Manuel Patino; Avinash Kambadakone; Dushyant Sahani
Journal:  AJR Am J Roentgenol       Date:  2016-08-04       Impact factor: 3.959

6.  Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.

Authors:  Sebastian Feuerlein; Daniel T Boll; Rajan T Gupta; Kristina I Ringe; Daniele Marin; Elmar M Merkle
Journal:  AJR Am J Roentgenol       Date:  2011-01       Impact factor: 3.959

Review 7.  Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.

Authors:  Yoon Jin Lee; Jeong Min Lee; Ji Sung Lee; Hwa Young Lee; Bo Hyun Park; Young Hoon Kim; Joon Koo Han; Byung Ihn Choi
Journal:  Radiology       Date:  2015-01-05       Impact factor: 11.105

8.  Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma.

Authors:  Sandro Rossi; Giorgia Ghittoni; Valentina Ravetta; Francesca Torello Viera; Laura Rosa; Martina Serassi; Mara Scabini; Alessandro Vercelli; Carmine Tinelli; Barbara Dal Bello; Peter N Burns; Fabrizio Calliada
Journal:  Eur Radiol       Date:  2008-03-28       Impact factor: 5.315

9.  Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus.

Authors:  Jin Woo Choi; Hyo-Cheol Kim; Jeong-Hoon Lee; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Hwan Jun Jae; Saebeom Hur; Myungsu Lee; Jin Wook Chung
Journal:  Eur Radiol       Date:  2016-08-11       Impact factor: 5.315

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  4 in total

1.  Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis.

Authors:  Hong-Ming Tsai; Meng-Zhi Han; Yih-Jyh Lin; Ting-Tsung Chang; Chiung-Yu Chen; Pin-Nan Cheng; Chiao-Hsiung Chuang; I-Chin Wu; Po-Jun Chen; Jui-Wen Kang; Yen-Cheng Chiu; Hung-Chih Chiu; Shih-Chieh Chien; Hsin-Yu Kuo
Journal:  Cancer Immunol Immunother       Date:  2021-01-06       Impact factor: 6.968

2.  Improvement of image quality and assessment of respiratory motion for hepatocellular carcinoma with portal vein tumor thrombosis using contrast-enhanced four-dimensional dual-energy computed tomography.

Authors:  Shingo Ohira; Naoyuki Kanayama; Kentaro Wada; Toshiki Ikawa; Takero Hirata; Noriko Kishi; Tsukasa Karino; Hayate Washio; Yoshihiro Ueda; Masayoshi Miyazaki; Masahiko Koizumi; Teruki Teshima
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

3.  Magnetic Resonance Image-Guided Hypofractionated Ablative Radiation Therapy for Hepatocellular Carcinoma With Tumor Thrombus Extending to the Right Atrium.

Authors:  Neris Dincer; Gamze Ugurluer; Teuta Zoto Mustafayev; Gorkem Gungor; Banu Atalar; Koray Guven; Enis Ozyar
Journal:  Cureus       Date:  2022-04-09

Review 4.  Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance.

Authors:  Hyo Jung Park; Nieun Seo; So Yeon Kim
Journal:  Korean J Radiol       Date:  2022-04-13       Impact factor: 7.109

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.